Skip to main content
. 2017 Jul 12;8(38):63911–63922. doi: 10.18632/oncotarget.19201

Figure 4. Changes in the PI3K/AKT/mTOR signaling pathway in A549 and A549/DDP cells following the Rap+T4 (0 h, 24 h), Wor+T4 (0 h, 24 h), and Per+T4 (0 h, 24 h) treatments.

Figure 4

(a) Following the Rap+T4 (0 h, 24 h), Wor+T4 (0 h, 24 h), and Per+T4 (0 h, 24 h) treatments, no differences were evident in the expression of PI3-K, PI3-P, AKT, TSC2, mTOR, p70S6K and 4E-BP1 in A549 lung cancer cells. No expression of LC3 in the control was observed; however, the abundant expression of LC3 was detected following the Rap+T4 (24 h), Wor+T4 (24 h), and Per+T4 (24 h) treatments. (b) Very low expression levels of phosphorylated PI3-K (p-PI3-K) were observed following the Rap+T4, Wor+T4, and Per+T4 treatments. No expression of p-PI3-K was observed in the Wor+T4 group at 24 h. Regarding p-AKT, no significant differences were found between the Rap+T4 group and the control group, and no expression of p-AKT was observed in the Wor+T4 and Per+T4 groups. No expression of p-mTOR and p-4E-BP1 was observed in the three groups, except for low expression levels in the Wor+T4 group at 0 h. No expression of p-p70S6K was observed in any of the groups, except for the control group. Very low expression levels of p-TSC2 were observed in the control group. (c and d) Similar changes were evident in A549/DDP cells.